NCT00042003 2024-08-02
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Astex Pharmaceuticals, Inc.
Phase 2 Completed
Astex Pharmaceuticals, Inc.
Novartis
Novartis
Takeda
Teva Branded Pharmaceutical Products R&D, Inc.
Novartis
Bristol-Myers Squibb